<DOC>
	<DOCNO>NCT00543712</DOCNO>
	<brief_summary>This multicenter , open-label , Phase II trial design evaluate efficacy safety PRO95780 give single agent patient advance chondrosarcoma . Up 90 patient confirm chondrosarcoma enrol .</brief_summary>
	<brief_title>A Study PRO95780 Patients With Advanced Chondrosarcoma ( APM4171g )</brief_title>
	<detailed_description />
	<mesh_term>Chondrosarcoma</mesh_term>
	<criteria>Ability understand willingness sign write informed consent document Age â‰¥ 18 year Histologic diagnosis chondrosarcoma , verifiable enrollment Measurable disease Previously treat incurable disease without option standard care therapy ECOG performance status 02 Life expectancy &gt; 3 month For patient reproductive potential ( male female ) , use reliable mean contraception ( e.g. , contraceptive pill , intrauterine device [ IUD ] , physical barrier ) throughout trial 1 year follow final exposure study treatment Systemic therapy radiotherapy within 4 week prior Day 1 Prior therapy agent target DR5 apoptosis pathway Major surgical procedure , open biopsy , significant traumatic injury within 4 week prior Day 1 , anticipation need major surgical procedure course study Other invasive malignancy within 5 year prior Day 1 Known active brain metastasis Uncontrolled intercurrent illness , include limited ongoing active infection require parenteral antibiotic enrollment Clinically significant , symptomatic cardiovascular disease , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia , Grade II great peripheral vascular disease , history major heart surgery within 6 month Day 1 , situation would likely limit compliance study requirement Known positive hepatitis C hepatitis B surface antigen History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Use anticoagulation therapy Participation clinical trial undergo investigational procedure within 30 day prior Day 1 Pregnancy breast feed Known sensitivity product administer study Any disorder compromise ability patient give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>synovial sarcoma</keyword>
	<keyword>APM4171g</keyword>
</DOC>